Patents by Inventor Jörn Lewin

Jörn Lewin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230287509
    Abstract: The present invention relates to the field of pharmacogenomics and in particular to detecting the presence or absence of methylated genomic DNA derived from liver cancer cells in biological samples such as body fluids that contain circulating DNA from the cancer cells. This detection is useful for an early and reliable diagnosis of liver cancer and the invention provides methods and oligonucleotides suitable for this purpose.
    Type: Application
    Filed: July 21, 2021
    Publication date: September 14, 2023
    Inventors: Jörn LEWIN, Denise KOTTWITZ
  • Publication number: 20220403473
    Abstract: The present invention relates to the field of pharmacogenomics and in particular to detecting the presence or absence of methylated genomic DNA derived from colorectal cancer cells in biological samples such as body fluids that contain circulating DNA from the cancer cells. This detection is useful for an early and reliable diagnosis of colorectal cancer and the invention provides methods and oligonucleotides suitable for this purpose.
    Type: Application
    Filed: December 16, 2020
    Publication date: December 22, 2022
    Inventors: Jörn LEWIN, Denise KOTTWITZ
  • Publication number: 20220372579
    Abstract: The present invention relates to the field of pharmacogenomics and in particular to detecting the presence or absence of hypermethylated DNA. The detection of CpG methylation in marker DNA is useful for the diagnosis of cancers and the invention provides improved methods for this purpose. These improved methods allow in particular for a more sensitive detection of methylated marker DNA with high backgrounds of unmethylated marker DNA.
    Type: Application
    Filed: April 26, 2022
    Publication date: November 24, 2022
    Inventors: Denise KOTTWITZ, Jörn LEWIN, Anne SCHLEGEL, Reimo TETZNER
  • Publication number: 20220243277
    Abstract: The invention provides methods, nucleic acids and kits for determining the prognosis of a subject having cancer. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients.
    Type: Application
    Filed: January 18, 2022
    Publication date: August 4, 2022
    Inventors: Jörn Lewin, Manuel Krispin
  • Patent number: 11345966
    Abstract: The present invention relates to the field of pharmacogenomics and in particular to detecting the presence or absence of hypermethylated DNA. The detection of CpG methylation in marker DNA is useful for the diagnosis of cancers and the invention provides improved methods for this purpose. These improved methods allow in particular for a more sensitive detection of methylated marker DNA with high backgrounds of unmethylated marker DNA.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: May 31, 2022
    Assignee: EPIGENOMICS AG
    Inventors: Denise Kottwitz, Jörn Lewin, Anne Schlegel, Reimo Tetzner
  • Patent number: 11261499
    Abstract: The invention provides methods, nucleic acids and kits for determining the prognosis of a subject having cancer. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: March 1, 2022
    Assignee: EPIGENOMICS AG
    Inventors: Jörn Lewin, Manuel Krispin
  • Publication number: 20200308656
    Abstract: The invention provides methods, nucleic acids and kits for determining the prognosis of a subject having cancer. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients.
    Type: Application
    Filed: March 10, 2020
    Publication date: October 1, 2020
    Inventors: Joern Lewin, Manuel Krispin
  • Publication number: 20200299779
    Abstract: The present invention relates to the field of pharmacogenomics and in particular to detecting the presence or absence of methylated genomic DNA derived from head and neck cancer cells in biological samples such as body fluids that contain circulating DNA from the cancer cells. This detection is useful for an early and reliable diagnosis of head and neck cancer and the invention provides methods and oligonucleotides suitable for this purpose.
    Type: Application
    Filed: February 12, 2020
    Publication date: September 24, 2020
    Inventors: Jörn LEWIN, Denise KOTTWITZ
  • Patent number: 10626462
    Abstract: The invention provides methods, nucleic acids and kits for determining the prognosis of a subject having cancer. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: April 21, 2020
    Assignee: EPIGENOMICS AG
    Inventors: Joern Lewin, Manuel Krispin
  • Publication number: 20190032148
    Abstract: The present invention relates to the field of pharmacogenomics and in particular to detecting the presence or absence of methylated ANKRD13B and/or FOXF2 DNA derived from a tumor in blood or blood-derived samples or in other body fluids that contain DNA released from a tumor. This detection is useful for a minimally invasive diagnosis of cancers and the invention provides methods and oligonucleotides suitable for this purpose.
    Type: Application
    Filed: January 27, 2017
    Publication date: January 31, 2019
    Applicant: EPIGENOMICS AG
    Inventors: Jörn LEWIN, Denise KOTTWITZ, Selina ESCHE
  • Publication number: 20180202006
    Abstract: The present invention relates to the field of pharmacogenomics and in particular to detecting the presence or absence of hypermethylated DNA. The detection of CpG methylation in marker DNA is useful for the diagnosis of cancers and the invention provides improved methods for this purpose. These improved methods allow in particular for a more sensitive detection of methylated marker DNA with high backgrounds of unmethylated marker DNA.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 19, 2018
    Inventors: Denise KOTTWITZ, Jörn LEWIN, Anne SCHLEGEL, Reimo TETZNER
  • Patent number: 9957575
    Abstract: The present invention relates to the field of pharmacogenomics and in particular to detecting the presence or absence of hypermethylated DNA. The detection of CpG methylation in marker DNA is useful for the diagnosis of cancers and the invention provides improved methods for this purpose. These improved methods allow in particular for a more sensitive detection of methylated marker DNA with high backgrounds of unmethylated marker DNA.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: May 1, 2018
    Assignee: EPIGENOMICS AG
    Inventors: Denise Kottwitz, Jörn Lewin, Anne Schlegel, Reimo Tetzner
  • Publication number: 20180023144
    Abstract: The invention provides methods, nucleic acids and kits for detecting lung carcinoma. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients.
    Type: Application
    Filed: August 9, 2017
    Publication date: January 25, 2018
    Inventors: Dimo Dietrich, Volker Liebenberg, Reimo Tetzner, Juergen Distler, Joern Lewin, Thomas Schlegel
  • Publication number: 20170283880
    Abstract: The invention provides methods, nucleic acids and kits for detecting, or for detecting and distinguishing between or among colorectal cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of and differentiation between said class of disorders, thereby enabling the improved diagnosis and treatment of patients.
    Type: Application
    Filed: April 3, 2017
    Publication date: October 5, 2017
    Inventors: Catherine Lofton-Day, Fabian Model, Andrew Sledziewski, Tamas Rujan, Joern Lewin, Juergen Distler
  • Publication number: 20170233820
    Abstract: The present invention relates to the field of pharmacogenomics and in particular to detecting the presence or absence of hypermethylated DNA. The detection of CpG methylation in marker DNA is useful for the diagnosis of cancers and the invention provides improved methods for this purpose. These improved methods allow in particular for a more sensitive detection of methylated marker DNA with high backgrounds of unmethylated marker DNA.
    Type: Application
    Filed: February 17, 2017
    Publication date: August 17, 2017
    Inventors: Denise KOTTWITZ, Jörn LEWIN, Anne SCHLEGEL, Reimo TETZNER
  • Patent number: 9624530
    Abstract: The present invention relates to methods and kits for preserving genomic DNA sequence complexity within chemically and/or enzymatically converted DNA by an enzyme or series of enzymes that adds a methyl group to a cytosine outside of CpG dinucleotide sequences of genomic DNA. Further, the present invention relates to methylation analysis of the genomic DNA.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: April 18, 2017
    Assignee: EPIGENOMICS AG
    Inventor: Joern Lewin
  • Publication number: 20170067119
    Abstract: The invention provides methods, nucleic acids and kits for detecting prostate cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients.
    Type: Application
    Filed: August 15, 2016
    Publication date: March 9, 2017
    Inventors: Andrew Z. Sledziewski, Shannon Payne, Matthias Schuster, Joern Lewin, Thomas Schlegel, Andrew M. Morotti
  • Publication number: 20160369356
    Abstract: Particular aspects provide methods, nucleic acids and kits for detecting cell proliferative disorders. Preferred aspects provide genomic sequences, the methylation patterns of which have substantial utility for the improved detection of said disorders, providing for improved diagnosis and treatment of same in patients.
    Type: Application
    Filed: September 6, 2016
    Publication date: December 22, 2016
    Inventors: Volker Liebenberg, Juergen Distler, Joern Lewin, Fabian Model, Reimo Tetzner, Rene Cortese, Dimo Dietrich, Thomas Schlegel
  • Publication number: 20160194722
    Abstract: The invention provides methods, nucleic acids and kits for detecting lung carcinoma. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients.
    Type: Application
    Filed: December 22, 2015
    Publication date: July 7, 2016
    Inventors: Dimo Dietrich, Volker Liebenberg, Reimo Tetzner, Juergen Distler, Joern Lewin, Thomas Schlegel
  • Publication number: 20150057183
    Abstract: Aspects of the present invention relate to the determination of the DNA methylation level at one or more CpG position within cells of a defined type in a tissue sample. This methylation level is deduced from the total DNA methylation level of all cells of the sample and from the content of said cells of interest. In aspects of the invention, the cell content is determined by means of histopatholoy, staining methods, antibodies, expression analysis or DNA methylation analysis.
    Type: Application
    Filed: November 6, 2014
    Publication date: February 26, 2015
    Inventors: Joern Lewin, Kurt Berlin